某院2018—2021年心肌能量代谢药物临床应用调查及用药合理性评价  

X hospital 2018-2021 Clinical Application Survey of Myocardial Energy Metabolism Drugs and Evaluation of Rationality of Medication

作　　者：周静[1] 刘复兴[1] ZHOU Jing;LIU Fuxing(Department of Medicine,Zhongxiang People’s Hospital,Zhongxiang 431900,Hubei,China)

机构地区：[1]钟祥市人民医院内科,湖北钟祥431900

出　　处：《中国药物滥用防治杂志》2021年第6期948-951,共4页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:分析2018—2021年心肌能量代谢药物临床应用情况,并对用药合理性进行评价。方法:选取2018年3月—2021年4月我院使用心肌能量代谢支持药物治疗的426例患者为试验对象,建立评估制度对用药合理性进行评估,统计药物利用指数(DUI)、用药频度(DDDs),评价每位患者使用心肌能量代谢药物情况和合理性。结果:426例使用心肌能量代谢支持药物治疗患者,均为单用药,注射用磷酸肌酸钠176例,每日用药量3 g,总用药量1485 g;使用左卡尼汀注射液150例,每日用药量3.50 g,总用药量1252 g;盐酸曲美他嗪片56例,每日用药量60 mg,总用药量40.64 g,均以心肌梗死、心绞痛患者最为常用;使用辅酶Q10片26例,以心律失常、心绞痛患者最为常用,每日用药量30 mg,总用药量8.59 g;使用左卡尼丁口服溶液8例,以心绞痛、冠心病患者最为常用,每日用药量10 ml,总用药量720 ml;注射用心肌肽10例,以心绞痛患者最为常用,每日用药量100 mg,总用药量4.60 g。同时出现用药不合理的有118例(27.70%),38例用药疗程不适宜,28例联合用药不适宜,22例药物配伍不适宜,17例用法用量不适宜,13例药物选择不适宜。结论:心肌能量代谢药物已成为心血管类疾病常用药,应用基本合理,但仍存在疗程、联合用药、用法用量等不适宜现象,对此需严格掌握每类药物用量、用法,从而促进药物合理应用。Objective:To analyze the clinical application of myocardial energy metabolism drugs from 2018 to 2021,and evaluate the rationality of the medication.Methods:A total of 426 patients who were treated with myocardial energy metabolism supportive drugs in our hospital from March 2018 to April 2021 were selected as subjects.The evaluation system was established to evaluate the rationality of medication.The drug utilization index(DUI)and DDDs were counted to evaluate the use and rationality of myocardial energy metabolism drugs in each patient.Results:426 patients treated with myocardial energy metabolism support drugs were all treated with single drug.176 patients were treated with sodium creatine phosphate for injection,3 g per day,and the total dosage was 1485 g.Using levocarnitine injection 150 cases,daily dosage 3.50 g,total dosage 1252 g.Trimetazidine hydrochloride tablets were used in 56 cases,with daily dosage of 60 mg and total dosage of 40.64 g.Myocardial infarction and angina pectoris were the most commonly used.Coenzyme Q10 tablets were used in 26 cases.Arrhythmia and angina pectoris were most commonly used.The daily dose was 30 mg and the total dose was 8.59 g.L-carnitine oral solution was used in 8 cases.Patients with angina pectoris and coronary heart disease were the most commonly used,with a daily dose of 10 ml and a total dose of 720 ml.Heart muscle peptide injection in 10 cases,the most commonly used in patients with angina,daily dose of 100 mg,the total dose of 4.60 g.There were 118 cases(27.70%)of irrational drug use,38 cases of inappropriate course of treatment,28 cases of inappropriate combination,22 cases of inappropriate drug compatibility,17 cases of inappropriate usage and dosage,13 cases of inappropriate drug selection.Conclusion:Myocardial energy metabolism drugs have become commonly used drugs for cardiovascular diseases,and their application is basically reasonable.However,there are still unsuitable phenomena such as the course of treatment,combined medication,usage and dosage,and it is n

关 键 词：心肌能量代谢药物 调查 合理性 安全性 

分 类 号：R95[医药卫生—药学]